HemaSphere
(Jun 2022)
P719: EFFICACY AND SAFETY OF BOSUTINIB IN LATER-LINE PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A SUB-ANALYSIS FROM THE PHASE 4 BYOND TRIAL
- C. Gambacorti-Passerini,
- T. H. Brümmendorf,
- T. Ernst,
- E. Leip,
- S. Purcell,
- A. Viqueira,
- F. J. Giles,
- G. Rosti,
- A. Hochhaus
Affiliations
- C. Gambacorti-Passerini
- 1 University of Milano-Bicocca, Monza, Italy
- T. H. Brümmendorf
- 2 Universitätsklinikum RWTH Aachen, Aachen
- T. Ernst
- 3 Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
- E. Leip
- 4 Pfizer Inc, Cambridge, United States of America
- S. Purcell
- 5 Pfizer Ltd, London, United Kingdom
- A. Viqueira
- 6 Pfizer SLU, Madrid, Spain
- F. J. Giles
- 7 Developmental Therapeutics Consortium, Chicago, United States of America
- G. Rosti
- 8 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
- A. Hochhaus
- 3 Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
- DOI
-
https://doi.org/10.1097/01.HS9.0000845760.12943.c0
- Journal volume & issue
-
Vol. 6
pp.
614
– 615
WeChat QR code